

0



Atty. Docket No.: 1657/1014B

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 28 2001

TECH CENTER 1600/2900

Application of: Endege, et al.
 Serial No.: 09/871,161
 Filed: May 31, 2001
 Entitled: NOVEL HUMAN GENES AND
 GENE EXPRESSION PRODUCTS

Examiner:

Group Art Unit 1631

Conf. No.: 8065

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

Nancy Arsenault

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
 Washington, D.C. 20231

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449
3. Copies of Cited References;
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 1657/1014B. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date:

September 25, 2001

Name: Paula Campbell Evans

Registration No.: 32,503

Customer No.: 27495

Palmer & Dodge LLP

One Beacon Street

Boston, MA 02108

Tel: 617-573-0100

RECEIVED

SEP 28 2001

TECH CENTER 1600/2900



Atty. Docket No.: 1657/1014B

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Endege, et al.
Serial No.: 09/871,161
Filed: May 31, 2001
Entitled: NOVEL HUMAN GENES AND
GENE EXPRESSION PRODUCTS

Examiner:

Group Art Unit: 1631

Conf. No.: 8065

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

Nancy Arsenault

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office. A listing of the cited documents is also enclosed. For the Examiner's convenience, Applicant encloses copies of cited documents referenced A-Z. Three of the cited documents, referenced 1-3 were unavailable and therefore are not enclosed. Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,

Date: September 25, 2001

Name: Paula Campbell Evans


Registration No.: 32,503

Palmer & Dodge LLP

One Beacon Street

Boston, MA 02108

Tel: 617-573-0100

USPTO Form 1449
U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT

Attorney Docket No.

1657/1014B

Serial No.

09/871,161

Applicant(s): Endege, et al.

Filing Date: May 31, 2001

Group: 1631

U.S. PATENT DOCUMENTS

Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	A.	4,824,776	Apr. 1989	Heller	435	6	
	B.	5,648,478	Jul. 1997	Henderson	536	241	
	C.	5,686,240	Nov. 1997	Schuchman, et al.	435	6	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
	D. ✓	WO 95 11923 A	05/04/95					
	E. ✓	EP 0 284 362 A	09/28/88	EP				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	1	XP002119315; Hillier L. et al.; "Stratagene human cDNA clone 550176 3' end", EMBL Sequence Database, Oct. 30, 1996, Heidelberg, Ger., Genome Research 6(9), 1996 p. 807-828.
	2	XP002119316, Marra M., et al.; "Mouse cDNA clone 779685 5' end", EMBL Sequence Database, Accession Number: AA415444, June 14, 1997, Heidelberg, Ger.
	F. ✓	XP002089887, Schweinfest, C.W., et al.; "Subtraction hybridization cDNA libraries from colon carcinoma and hepatic cancer", Gene Analysis Techniques, vol. 7, Jan. 1, 1990, pp. 64-70.
	G. ✓	XP002104685, Vider, B., et al.: "Human colorectal carcinogenesis is associated with deregulation of homeobox gene expression", Biochemical and Biophysical Research Communications, vol. 232, no. 3, Mar. 1997, pp. 742-748.
	H. ✓	XP002024627, Jau Min Wong, et al.; "Ubiquitin-Ribosomal protein S27A gene overexpresses in human colorectal carcinoma is an early growth response gene", Cancer Research, vol. 53, no. 8, 15 April 1993, pp. 1916-1920.
	I. ✓	XP002089891, Van Belzen, N., et al.; "A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms", Laboratory Investigation, vol. 77, no. 1, 1 July 1997, pp. 85-92.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.

USPTO Form 1449
Patent and Trademark Office

Department of Commerce

INFORMATION DISCLOSURE STATEMENT

Attorney Docket No.

1657/1014B

Serial No.

09/871,161

Applicant(s): Endege, et al.

Filing Date: May 31, 2001

Group: 1631

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation
						YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

J.	✓	XP002119317, Kondoh, N., et al.; "Differential expression of S19 ribosomal protein, laminin-binding protein and human lymphocyte antigen class-1 messenger RNAs associated with colon-carcinoma progression and differentiation", Cancer Research, vol. 42, no. 4, 15 February 1992, pp. 791-796.
3		XP002119318, Kutay, U., et al.; "A human homologue of yeast Mtr10p and its role in nuclear protein import", EMBL Sequence Database, 10 May, 1999, Heidelberg, Ger.
K.	✓	XP002126133, EMBL, Database Hum2:SEQ. ID HS23K20, "Human DNA sequence from clone 23K20 on chromosome Xq25-26.2"
L.	✓	XP002126134; EMBL Database Hum2:SEQ. ID HS24M15, "Human DNA sequence from PAC 24M15 on chromosome 1, contains tenascin-R (restritin) EMBL Database Accession No. HsZ4M15.
M.	✓	Ausubel, et al., Current Protocols in Molecular Biology, Vol. 1 and 2, John Wiley & Sons, NY (1988) (Title Page Only).
N.	✓	Altschul, et al., "Issues in searching molecular sequence databases", Nature Genetics 6:119 (1994).
O.	✓	Altschul, et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs" Nucleic Acids Research 25:3389 (1997).
P.	✓	Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2 nd Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY (1987) (Title Page Only).
Q.	✓	Daitchenko, et al., "Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cDNA probes and libraries" PNAS, 93:6025-6030 (1996).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


**Copies of references not provided at the time of this submission.

RECEIVED

SEP 28 2001

Page 3 of 3

TECH CENTER 1600/2900

USPTO Form 1449
Patent and Trademark Office U.S. Department of Commerce

INFORMATION DISCLOSURE STATEMENT

Attorney Docket No.

1657/1014B

Serial No.

09/871,161

Applicant(s): Endege, et al.

Filing Date: May 31, 2001

Group: 1631

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation
						YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

R.	✓	Gurskaya, et al., "Equalizing CDNA Subtraction Based on Selective Suppression of Polymerase Chain Reaction: Cloning of Jurkat Cell Transcripts Induced by Phytohemagglutinin and Phorbol 12-Myristate 13-Acetate", Analytical Biochemistry 230:90-97 (1996).
S.	✓	Von Stein, et al., "A high throughput screening for rarely transcribed differentially expressed genes", Nucleic Acids Research 25 (13):2598-2602 (1997)
T.	✓	Jin, et al., "Differential Screening of a Subtracted cDNA Library: A Method to Search for Genes Preferentially Expressed in Multiple Tissues", Biotechniques 23:1084-1086 (1997).
U.	✓	Mullis, et al., "Specific Synthesis of DNA in Vitro via a Polymerase-Catalyzed Chain Reaction", Methods Enzymol 155:335-350 (1987).
V.	✓	Harlow & Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Press, (1988) (Title Page Only).
W.	✓	Summary of BLAST searching (544 sequences).
X.	✓	Hillier, et al., "Generation and analysis of 280,000 human expressed sequence tags", Genome Research, vol. 6, no. 9, 1996, pages 807-828.
Y.	✓	Marra M., et al., vol. 25a10.s1 Knowles Solter mouse 2 cell Mus musculus cDNA clone, GenCore version 4.5, Accession AA415444, The WashU-HHMI Mouse EST project, 10/16/97. GenBank Assession No. AA415444.
Z.	✓	Tanaka, et al., "Construction of a normalized directionally cloned CDNA library from adult heart and analysis of 3040 clones by partial sequencing", Genomics 35, 1996, pages 231-235.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.